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Abstract
Background: As the role of palliative care (PC) has yet to be clearly defined in patients with heart failure (HF),
such patients may face barriers regarding PC referral. In order to maximally meet the needs of HF patients, it is
necessary to understand how they compare to the classic PC population: patients with cancer.
Objective: To characterize the unresolved symptom and treatment needs with which patients with HF and those
with cancer present to PC.
Methods: We used data from the Palliative Care Research Registry (PCRR), a repository of quality im-
provement data from three community-based PC organizations. We abstracted first PC visit data from the PCRR
for patients with primary diagnoses of HF or cancer seen between 2008 and 2012. We assessed the association
of primary diagnosis (i.e., HF or cancer) on three outcomes: unresolved symptoms, treatment gaps, and a
composite indicator of symptom control and quality of life. Analyses included descriptive statistics and mul-
tivariate Poisson regression.
Results: Our analytic sample comprised 334 patients with HF and 697 patients with cancer, the majority of
whom were white and male. Compared to patients with cancer, patients with HF presented with fewer unre-
solved symptoms, both overall and at moderate/severe distress levels. Patients with HF more commonly
reported moderately/severely distressful dyspnea (25% versus 18%, p = 0.02), and more commonly experienced
dyspnea-related treatment gaps (17% versus 8%, p < 0.001).
Conclusions: Patients with HF possess care needs that are squarely within the purview of PC. Future work is
needed to delineate how PC referral policies should be refined to optimize PC access for patients with HF.
Introduction
H istorically, palliative care (PC) in the United Stateshas largely served patients with cancer.1 Nevertheless,
patients with other serious illnesses, including heart failure
(HF), may benefit from PC. HF is a progressive condition
that affects more than 5,000,000 Americans,2 and is asso-
ciated with significant physical and psychosocial distress
for patients and caregivers.3–7 Given its prevalence and
improved survival resulting from life-prolonging therapies,
the burden of chronic HF is greater than ever and is expected
to grow.8
Internationally, numerous consensus statements support
PC for patients with HF, ranging from specialist PC consul-
tation to comanagement models.7,9–11 In the United States,
the American College of Cardiology recommends PC for
patients with advanced disease,9 however, patients with HF
access palliative services far less often than patients with
1Center for Research on Health Care, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of
Medicine, Pittsburgh, Pennsylvania.
2Department of Health Policy and Management, Gillings School of Global Public Health, 5Cecil G. Sheps Center for Health Services
Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
3Center for Learning Health Care, Duke Clinical Research Institute, 4Division of Medical Oncology, Duke University School of
Medicine, Duke University Medical Center, Durham, North Carolina.
6Phoenix VA Health Care System, Phoenix, Arizona.
7Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, Durham, North Carolina.
Accepted November 4, 2013.
JOURNAL OF PALLIATIVE MEDICINE
Volume 17, Number 4, 2014
ª Mary Ann Liebert, Inc.
DOI: 10.1089/jpm.2013.0526
475
cancer.1 Although patients with HF and those with cancer
exhibit similar disease-related burdens,12 patients with HF
with worse health status experience greater physical and
psychological symptom burdens.6 Patients with HF and those
with cancer (and their caregivers) may differ in other ways.
First, patients with HF may be less enagaged in health care
decision-making and have less information regarding their
illness and treatment options.13,14 Second, patients with HF
experience poorer care coordination.13,15,16 Third, the pattern
of decline in physical and psychological well-being vastly
differs between patients with HF and patients with cancer.13
Last, the unpredictable trajectory of HF may impede PC re-
ferral.15–18 Moreover, because provider-related factors may
delay PC referral among patients with HF,16 they may present
with more advanced symptoms than patients with cancer.
Community-based PC is expanding in the United States,19,20
and holds promise to increase PC access for patients with HF.
As such, it is important for community-based PC providers to
understand the unmet palliative needs of patients with HF at
first consultation, and how they differ from those of patients
with cancer. Our goals are to: (1) describe patients with HF
and patients with cancer receiving community-based PC; (2)
determine the impact of having HF versus cancer on unre-
solved symptoms and treatment gaps; and (3) assess associ-
ations between primary diagnosis and outcomes. We seek to
provide potential priorities for initial community-based PC
consultations of patients with HF and those with cancer.
Methods
Data
We analyzed data from the Palliative Care Research Registry
(PCRR), the repository of retrospective quality improvement
data for the Carolinas Palliative Care Consortium. Estab-
lished in 2008, the Consortium is a community-academic
partnership between three North Carolina PC organizations
and Duke University.21,22 We extracted data from patients’
initial PC visits between June 1, 2008 and January 1, 2012.
At each PC visit, Consortium providers collected patient-
or proxy-reported data on the distress of 11 symptoms: agi-
tation, anorexia, anxiety, constipation, depression, diarrhea,
dyspnea, fatigue, insomnia, nausea, and pain using the
McCorkle Symptom Distress Scale.23 Symptom tolerability
was also asssessed.
Measures
Our dependent variables were: (1) number of unresolved
symptoms; (2) number of treatment care gaps; and, (3) pal-
liative care patient health status (PC-PHS), a composite in-
dicator of adequate symptom control and QOL. Unresolved
symptoms are those rated as causing moderate or severe
distress for each of the 11 symptoms in the PCRR (range, 0–
11). Thus, ‘‘unresolved’’ signifies symptom distress persist-
ing at the initial PC consultation—likely reflecting care
received prior to PC referral. Somatic symptom burden (i.e.,
frequency and severity) may be a resonable indicator of latent
emotional distress and poor quality of life in cardiovascular
disease.24,25 A treatment gap was defined as the lack of a
documented pharmacologic or nonpharmacologic interven-
tion for a symptom whose distress was rated as moderate or
severe. As interventions were documented for pain, dyspnea,
constipation, and depression, treatment gap counts ranged
between 0–4. Similar to unresolved symptoms, our measure
reflects care received prior to PC referral.
Finally, PC-PHS is a composite indicator of symptom
control and quality of life. We focused on pain and dyspnea,
which are relevant to patients with HF and those with can-
cer26,27 and are often targets of PC interventions. Providers
asked patients about both current and maximum tolerable
levels of each symptom. Patients were considered to have
adequate control if current symptoms were less than the
maximum tolerable level, or the patient reported no current
symptom. Although this may not constitute the ideal goal for
symptom resolution, it represents a minimum standard of
control. Furthermore, it is a patient-centered approach, as-
sessing treatment effectiveness based on a specific patients’
symptom experience. Quality of life was assessed with a sin-
gle item (poor, fair, good).28 Given that only 5% of patients
reported good quality of life, we created a binary measure
(poor versus fair/good QOL). The resulting PC-PHS variable
is a binary indicator with 1 (better health status) indicating all
3 criteria were met (i.e., controlled pain, controlled dyspnea,
and fair/good quality of life), and 0 otherwise.
Our independent variable was primary diagnosis (i.e., HF
or cancer). Diagnostic codes used to identify cohorts are
provided in Table 1.
Control variables included: patient age, gender, race, care
setting, and respondent (i.e., patient-reported, proxy-reported).
Performance status was assessed using the Palliative Per-
formance Scale (PPS).30,31 We transformed PPS into a three-
category variable for clinical relevance (i.e., 0–30, low; 40–60,
medium; 70–100, high).32,33
Statistical analysis
All analyses were cross-sectional, patient-level, and as-
sessed at the time of first PC visit. First, we used Pearson’s v2
tests, Student’s t tests, and Wilcoxon-Mann-Whitney tests to
examine bivariate differences by primary diagnosis. Next, we
estimated risk ratios (RRs) to assess the effect of primary
diagnosis on the probability of the PC-PHS outcome. We
calculated RRs using modified Poisson regression with robust
errors.34,35 Statistical tests were two-tailed with a critical a-
level of 0.05. We conducted numerous sensitivity analyses, as
well as assessments of model fit (e.g., Akaike’s Information
Criterion [AIC], deviance). Analyses were conducted using
Stata/IC, version 12 (StataCorp, College Station, TX).36 This
study was approved by the Institutional Review Boards of
Duke University and the University of North Carolina.
Table 1. Diagnostic Codes Used
to Identify Patient Cohorts
Cohort ICD-9-CM Diagnostic Codes
Heart failure29 428.xx (heart failure); 429.3
(cardiomegaly); 402.01 (malignant
hypertensive heart disease with HF);
402.11 (benign hypertensive heart
disease with HF); 402.91 (unspecified
hypertensive heart disease with HF);
and, 425.xx (cardiomyopathy).
Cancer 140-239.9
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Results
Of 1031 patients meeting study criteria, 334 (32%) had a
primary diagnosis of HF; their characteristics are presented in
Table 2. Most patients had a do-not-resuscitate order. The
median PPS score for all patients was 40%, indicating pre-
dominantly bedridden patients with extensive evidence of
disease. Approximately half of each disease group reported
fair/good quality of life. Compared to patients with cancer,
patients with HF were significantly older (84 versus 71 years,
p < 0.001), had one or more prior hospitalization in the pre-
ceding 6 months (81% versus 63%, p < 0.001), and likelier to
reside in a nursing home (18% versus 4%, p < 0.001).
Patients with HF presented with fewer moderately and
severely distressful unresolved symptoms than did patients
with cancer (1.77 versus 2.24, p = 0.0001) and overall (3.36
versus 3.87, p = 0.0002), patients with HF, relative to patients
with cancer, less frequently rated the following symptoms as
moderately/severely distressful: anorexia (29% versus 46%,
p < 0.001), pain (19% versus 32%, p < 0.001), insomnia (14%
versus 20%, p = 0.02), anxiety (12% versus 20%, p = 0.002),
constipation (8% versus 15%, p = 0.004), and nausea (4%
versus 13%, p < 0.001). Only dyspnea was more commonly
reported by patients with HF than patients with cancer as
moderately/severely distressful (25% versus 18%, p = 0.02;
Fig. 1). Patients with HF experienced more dyspnea treat-
ment gaps (17% versus 8%, p < 0.001; Fig. 2); cancer patients
had more constipation-related treatment gaps (11% versus
6%, p = 0.008).
In bivariate analysis, diagnosis was not associated with PC-
PHS (unadjusted RR: 1.20, 95% confidence interval [CI]: 0.96,
1.50, Table 3). However, after adjusting for clinical and de-
mographic factors, patients with HF had lower probability of
positive health status (adjusted RR: 0.70, 95% CI: 0.55, 0.90).





Characteristic n (%) n (%) p value
n 334 697
Age in years, median [range] 84 [33–102] 71 [12–101] <0.001
Male gender 138 (41) 327 (47) 0.09
Race 0.001
White 302 (90) 602 (86)
Black 16 (5) 78 (11)
Other or unknown 16 (5) 17 (2)
Advance care planning activities completed prior to or during initial palliative care visit
Do-not-resuscitate status declaration 217 (65) 472 (68) 0.64
Living will completed 136 (41) 249 (36) 0.003
MOST form completed 16 (5) 24 (3) 0.30
Designation of healthcare surrogate 191 (57) 472 (68) <0.001
Number of hospitalizations within 6 months before first palliative care visit <0.001
0 64 (19) 256 (37)
1 90 (27) 183 (26)
2 53 (16) 97 (14)
3 28 (8) 38 (5)
<3 17 (5) 15 (2)
Unknown 82 (25) 108 (15)
Care setting at time of first palliative care visit <0.001
Hospital inpatient 230 (69) 544 (78)
Nursing home or assisted living facility 61 (18) 30 (4)
Patient home 25 (8) 83 (12)
Outpatient clinic 1 (0.3) 6 (0.7)
Respondent 0.03
Patient 222 (66) 507 (73)
Caregiver or provider 110 (33) 183 (26)
Palliative Performance Scale, median [range] 40 [10–80] 40 [10–90] 0.27
Low (10%–30%) 92 (28) 236 (34)
Medium (40%–60%) 154 (46) 296 (42)
High (70%–100%) 13 (4) 74 (11)
General quality of life rating 0.99
Poor 134 (40) 301 (43)
Fair/good 153 (46) 344 (49)
Values may not sum to 100 due to rounding and/or missing data. The Palliative Performance Scale rates functional status across five
domains from 0%–100% in 10-percentage point increments, with greater scores indicating higher performance. v2 tests of independence
were calculated for categorical variables, Student’s t tests were used for normally distributed continuous variables, and Wilcoxon-Mann-
Whitney tests calculated for interval or non-normally distributed continuous outcomes.
MOST, Medical Orders for Scope of Treatment.
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Discussion
Patients with HF possess care needs that are clearly within
the purview of PC. Prior work comparing the physical
and psychosocial needs of patients with HF and those with
cancer found the groups to be indistinguishable vis-à-vis
symptom burden, despite differences regarding specific
symptom prevalence.6,37 Our conclusions generally support
these findings. We found that patients with cancer reported
more unresolved moderately/severely distressful symptoms
(2.24 versus 1.77). Whether this difference is sufficient to affect
clinical decisionmaking is unknown; our experience suggests
that symptom prioritization becomes paramount when people
suffer from multiple problems simultaneously. Nevertheless,
the question remains whether cumulative symptom burden or
distress from a specific symptom prompts provider intervention.
Echoing previous work,37,38 we found greater dyspnea in pa-
tients with HF than in patients with cancer; dyspnea, like pain, is
a high-priority symptom that must be addressed, otherwise
quality of life degrades and caregiver burden escalates.38–42
Last, having HF was associated with poorer health, even after
controlling for the advanced age of our patients with HF. Our
findings suggest that patients with HF and patients with cancer
are appropriate for PC, however, the pattern of burden appears
to differ between the two illnesses. Therefore, the portfolio of
palliative interventions must be appropriately tailored.
FIG. 2. Prevalence of treatment gaps at first palliative care consultation. We defined a treatment gap as the lack of a
documented intervention for a symptom whose distress was rated as moderate or severe. *Pearson’s v2 test indicates
significant difference in treatment gap prevalence between heart failure patients and patients with cancer at the a = 0.05
level.
FIG. 1. Prevalence of unresolved symptoms at first palliative care consultation. A symptom was defined as unresolved
when the distress that it caused was rated as either moderate or severe. *Pearson’s v2 test indicates significant difference in
unresolved symptom prevalence between heart failure patients and patients with cancer at the a = 0.05 level.
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Several limitations merit comment. First, PC-PHS is an
exploratory composite measure. Although it has not yet been
formally validated, it has face validity based on clinical and
intuitive logic. Second, our cross-sectional study means that
conclusions be judiciously interpreted. Third, data come from
a community-based PC consortium in North Carolina and
our patients were referred for PC; these factors may limit
generalizability.
Ours is the first HF-focused analysis of community-based PC
in the United States. We hope that it will serve to further de-
scribe a model of care through which we may expect a growing
number of patients with HF to receive supportive services.7,19
With an estimated additional 3,000,000 Americans to be diag-
nosed with HF by 2030,43 our work can spark discussion re-
garding PC workforce planning, ensuring that PC teams have
the skills and resources necessary to care for people with HF.
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